Items where authors include "Coates, L"

Article

van Duren, BH, Wignall, A, Rangan, A et al. (3 more authors) (2021) To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery? Rheumatology Advances in Practice, 5 (3). rkab057. ISSN 2514-1775

Packham, JC, Abraham, S, Kirkham, B et al. (8 more authors) (2018) A new era for collaboration? Rheumatology, 57 (5). pp. 775-776. ISSN 1462-0324

Rothery, C, Bojke, L, Richardson, G et al. (6 more authors) (2016) A discrete choice experiment to explore patients’ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. Clinical Rheumatology, 35 (12). pp. 2967-2974. ISSN 0770-3198

Coates, L and Helliwell, P (2016) More than meets the eye? The Lancet, 388 (10060). e15-e15. ISSN 0140-6736

Moverley, A, Coates, L, Marzo-Ortega, H et al. (5 more authors) (2015) A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F)). Clinical Rheumatology, 34 (8). pp. 1407-1412. ISSN 0770-3198

Bowes, J, Orozco, G, Flynn, E et al. (14 more authors) (2011) Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Annals of the Rheumatic Diseases, 70 (9). pp. 1641-1644. ISSN 0003-4967

Bowes, J, Eyre, S, Flynn, E et al. (17 more authors) (2011) Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Annals of the Rheumatic Diseases, 70 (6). pp. 1016-1019. ISSN 0003-4967

Conference or Workshop Item

Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Orbai, A-M, Coates, L, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Tucker, L, Helliwell, P orcid.org/0000-0002-4155-9105, Coates, L et al. (1 more author) (2021) Which composite measure best reflects disease activity and predicts treatment change in psoriatic arthritis? In: British Society for Rheumatology Annual Conference 2021, 26-28 Apr 2021, Virtual.

Mease, P, Coates, L, Van den Bosch, F et al. (7 more authors) (2020) Effect of Filgotinib on the Complete Resolution of Enthesitis in Psoriatic Arthritis (PsA) Patients: 52-week Results from EQUATOR2. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Ritchlin, C, Gossec, L et al. (12 more authors) (2020) Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: ACR Convergence 2020, 05-09 Nov 2021, Virtual.

Orbai, A-M, Coates, L, Deodhar, A et al. (8 more authors) (2020) Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Gladman, D, Van den Bosch, F et al. (10 more authors) (2020) Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA). In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Helliwell, P orcid.org/0000-0002-4155-9105, Mease, P, Kavanaugh, A et al. (9 more authors) (2020) What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2020) Long-Term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2020) Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.

Coates, L, Mease, P, Gladman, D et al. (8 more authors) (2019) Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study. In: 2019 ACR/ARP Annual Meeting Minutes, 08-13 Nov 2019, Atlanta, Georgia, USA.

Coates, L, Merola, J, Mease, P et al. (10 more authors) (2019) The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.

Helliwell, P, Bushmakin, A, Gladman, D et al. (5 more authors) (2019) Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.

Coates, L, Bushmakin, A, FitzGerald, O et al. (5 more authors) (2019) Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.

Gladman, D, Coates, L, Wu, J et al. (6 more authors) (2019) Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo. In: 2019 ACR/ARP Annual Meeting, 08-13 Nov 2019, Atlanta, Georgia, USA.